FebriDx U.S. Rollout and Reimbursement Update - Amended
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. has issued an amended announcement regarding the U.S. rollout and reimbursement update for FebriDx, correcting a date reference related to the upcoming flu season. The update highlights encouraging reimbursement signals, with a significant majority of submitted claims being paid and average payments exceeding the Medicare fee schedule rate. Commercial progress includes the use of FebriDx in numerous urgent care clinics, with ongoing evaluations and implementations at additional pilot sites. The company plans to continue supporting customers with reimbursement education as they prepare for the next flu season.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings CallLumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- FebriDx U.S. Rollout and Reimbursement Update
- FebriDx Paediatric Study Enrolment Milestone Achieved
- Response to ASX Aware Letter
- Prospectus
- Lumos secures new contract manufacturing agreement
Later from Lumos Diagnostics
- FebriDx Commercial Traction Across Priority US Accounts
- Application for quotation of securities - LDX
- Section 708A Cleansing Statement
- Change of Director's Interest Notice - DW
- Lumos Secures Distribution for FebriDx in Romania
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics